- Home
- PNR vs BBIO Comparison
PNR vs BBIO Comparison
Compare PNR & BBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PNR | BBIO |
|---|---|---|
| Founded | 1966 | 2015 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 16.9B | 14.7B |
| IPO Year | N/A | 2019 |
Fundamental Metrics
Financial Performance| Metric | PNR | BBIO |
|---|---|---|
| Price | $108.16 | $79.71 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 14 | 21 |
| Target Price | ★ $117.54 | $78.90 |
| AVG Volume (30 Days) | 1.4M | ★ 2.6M |
| Earning Date | 02-03-2026 | 02-19-2026 |
| Dividend Yield | ★ 1.01% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 3.93 | N/A |
| Revenue | ★ $4,128,399,999.00 | $353,780,000.00 |
| Revenue This Year | $2.97 | $128.07 |
| Revenue Next Year | $4.42 | $77.53 |
| P/E Ratio | $27.26 | ★ N/A |
| Revenue Growth | 0.83 | ★ 62.46 |
| 52 Week Low | $74.25 | $28.33 |
| 52 Week High | $113.95 | $79.88 |
Technical Indicators
Market Signals| Indicator | PNR | BBIO |
|---|---|---|
| Relative Strength Index (RSI) | 59.29 | 63.06 |
| Support Level | $103.32 | $73.77 |
| Resistance Level | $107.67 | $78.13 |
| Average True Range (ATR) | 2.86 | 3.59 |
| MACD | 0.52 | 0.02 |
| Stochastic Oscillator | 90.48 | 85.01 |
Price Performance
Historical ComparisonAbout PNR Pentair plc.
Pentair is a global leader in the water treatment industry, with 10,000 employees and a presence in 25 countries. Its business is organized into three segments: pool, water technologies, and flow. The company offers a wide range of water solutions, including energy-efficient swimming pool equipment, filtration solutions, and commercial and industrial pumps. Pentair generated approximately $4.1 billion in revenue in 2024.
About BBIO BridgeBio Pharma Inc.
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis), is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.